US Trade Rep Recommends Tariffs On China-Sourced Medtech, BioPharma Products
Executive Summary
In addition to taxing foreign-made steel imports from certain countries, the US Trade Representative's office will soon recommend tariffs against Chinese-made biopharma and advanced medtech products, and other products in US/China competitive industries.
You may also be interested in...
Industry Gives US Trade Rep 12 Reasons Why Tariffs on Chinese Medtech Imports Are A Bad Idea
The US Trade Representative office's decision in March to include devices, imaging machines and diagnostics on a list of Chinese imports destined for a 25% tariff has riled up the industry. A half-dozen medtech organizations protested the move in comments and testimony this week, supplying USTR with 12 reasons why the tariffs are a very bad idea.
AdvaMed To Plead With USTR To Spare Medtech In China Tariffs
In prepared remarks shared with Medtech Insight, AdvaMed plans to argue that tariffs imposed on medtech products made in China would disrupt an ongoing "action plan" the industry is pursuing to achieve reciprocal market access between the US and China for the industry.
Trump Administration Wants Tariffs On 49 China-Imported Medtech Products
Citing China's "unfair trade practices on the forced transfer of US technology and intellectual property," the White House on April 3 proposed a 25% tariff on 49 types of Chinese medical devices, including products from advanced imaging units to hearing aids. Industry advocacy group AdvaMed says some members are "surprised and disappointed" by the inclusion of devices on the list.